'Regenerative Medicine Market Will Reach $1.4 Billion in 2012' States Visiongain Report

LONDON, September 11, 2012 /PRNewswire/ --

A new report by visiongain predicts that the overall world market for translational regenerative medicine will reach $1.4bn in 2012. That revenue forecast and others appear in Translational Regenerative Medicine Market Prospects 2012-2022, published in September 2012. Visiongain is a business information provider based in London, UK.

Visiongain forecasts that the overall regenerative medicine market will multiply in size from 2012 to 2022. The regenerative medicine industry is in its infancy; however marketed products have achieved commercial success. Visiongain believes the strength of the regenerative medicine market is its potential to treat a plethora of diseases. Growth of the market will be driven by targeting serious, prevalent disorders such as cancer, cardiovascular disease and diabetes. In these areas, the potential for regenerative medicine technologies is vast, and regulatory and cultural uncertainties about the field will not derail its progress from 2012 to 2022.

Dr Peter Williamson, a pharmaceutical industry analyst in visiongain, said: "Regenerative medicine is a market with huge potential. The key to its future lies in the successful approval and commercialisation of new products. We have already seen commercial success in the tissue engineering sector with products such as Dermagraft and Apligraf. It is important that companies, reimbursement agencies and regulatory authorities learn lessons from these achievements, ultimately guiding efficient developmental processes. In addition, advances in the scientific understanding of cellular mechanisms and how they aid and influence regeneration will strengthen these processes.

"Our study notes that widespread commercialisation will be challenging during the forecast period 2012 to 2022. However, these challenges will be overcome by the maturing market, investment from pharmaceutical companies and the creation of regenerative medicine centres. In addition, there are growing numbers of regenerative medicine start-up companies and research and development (R&D) for regenerative medicine is strong."

Visiongain's report shows revenue forecasts to 2022 at overall world market, submarket, product and regional level. It forecasts these world-level submarkets:

• Tissue-engineered products
• Stem cell applications
• Gene therapy
• Other uses.

The investigation predicts revenues of leading products in the market: Apligraf, Dermagraft, DeNovo NT and Osteocel Plus. Research, data and analyses cover activities of Shire Regenerative Medicine, Advanced Cell Technology, Athersys, Mesoblast, Geron and other companies.

That study discusses R&D and commercial news, shows research interviews and predicts revenues to 2022 in leading regional markets. The work analyses the United States, Europe (EU, Norway, Switzerland and Iceland), Asia Pacific (Japan, China, India and South Korea), and the rest of the world (as a group), including Brazil and Russia.

Translational Regenerative Medicine: Market Prospects 2012-2022 adds to visiongain's range of analytical reports on industries and markets in healthcare.

For sample pages and further information concerning the Translational Regenerative Medicine: Market Prospects 2012-2022 please visit: http://www.visiongain.com/Report/886/Translational-Regenerative-Medicine-Market-Prospects-2012-2022

For an executive summary of this report or to order it today please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44(0)20-7336-6100

Companies Listed
Aastrom Biosciences
Advanced BioHealing
Advanced Cell Technology
Advanced Technologies and Regenerative Medicine
Aldagen
AlloSource
AlphaTec Spine
ALS Therapy Development Institute (US)
Altrika
Amedica
American Academy of Ophthalmology
Amgen
Amorcyte
Amsterdam Molecular Therapeutics (AMT)
AnGes MG
Angioblast Systems
Angiotech
AnorMED
Anterogen
Apceth
ArBlast
ARCH Venture Partners
Ark Therapeutics
AstraZeneca
Athersys
Avita Medical
AxoGen
Baxter Healthcare
Baylor College of Medicine
Beike Biotechnology
Benda Pharmaceutical
Beth Israel Deaconess Medical Center
BioD LLC
BioDlogics
Biogenea Pharmaceuticals
Bioheart
BioMed Realty Trust
BioSante Pharmaceuticals
BioTime
BioTissue
bluebird bio
Boehringer Ingelheim
BrainStorm
BresaGen
Brown University
California Institute of Regenerative Medicine (CIRM)
Canaan Partners
Capricor
Cardio3 BioSciences
Cardiogenesis Corporation
Catalan Institution for Research and Advanced Studies
Cellartis
CellCoTec
Cellerant Therapeutics
Cellerix
Cellonis Biotechnology
CellSeed
Center for Commercialization of Regenerative Medicine (Canada)
Center for Medicare and Medicaid Services (US)
Cephalon
Ceregene
CHA Biotech
Cha General Hospital, Seoul
Children's Hospital of Philadelphia
Chinese Academy of Sciences
Chinese Ministry of Science and Technology
Clinical Cell Culture
co.don AG
Cold Genesys
Committee for Advanced Therapies (CAT)
Crawford Healthcare
Cryo Center Saint-Petersburg
CyThera
Cytori Therapeutics
Daiichi Sankyo
Dendreon
Department of Health (UK)
DePuy Mitek
Drugs Controller General of India (DCGI)
Eli Lilly
Emory University
Epeius Biotechnologies
European Medicines Agency (EMA)
EyeCyte
FCB-Pharmicell
Fibrocell Science
Food and Drug Administration (US FDA)
Forbion Capital Partners
Gamida Cell
Garnet Biotherapeutics
Gemabank
Genentech
Genethon
Genetic Engineering Approval Committee (GEAC)
GenVec
Genzyme
Geron
Geron Bio-Med
GlaxoSmithKline
Hadassah Medical Organization
Harvard Medical School
Health Canada
Hefei Meifu Bio-Tech
Histogenics
Humacyte
Human Stem Cell Institute
Ilika
ImmunoCellular Therapeutics
Integra
Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami
International Society for Stem Cell Research (ISSCR)
Introgen
ISTO Technologies
Ixion Biotechnology
Japan Patent Office (JPO)
Japanese Society for Regenerative Medicine (JSRM)
Japanese Tissue Engineering Co
Jennerex Biotherapeutics
John Hopkins Cancer Centre
Johnson & Johnson (J&J)
Juvenile Diabetes Research Foundation (JDRF)
Kanazawa University
Kinetic Concepts
Kobe Pharmaceutical University
Korea Food and Drug Administration (KFDA)
LecTec Corporation
LifeCell
Lonza
Lund University Stem Cell Center
Massachusetts Institute of Technology (MIT)
Massey Cancer Center, Virginia Commonwealth University
Medical Research Council (UK)
Medicines and Healthcare Products Regulatory Agency (MHRA, UK)
Medipost
MediStem
Medtronic
Merck & Co.
Merck Millipore (a division of Merck KGaA)
Mesoblast
Ministry of Health (China)
Ministry of Health, Labour and Welfare (MHLW) Japan
MolMed
Moorfields Eye Hospital (UK)
Motor Neurone Disease Association (MNDA, UK)
Muscular Dystrophy Association (US)
Musculoskeletal Transplant Foundation
Myriad Genetics
Mytogen
Nagoya University
National Cancer Institute
National Institute for Health and Clinical Excellence (NICE, UK)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institutes of Health (NIH)
National Tissue Engineering Center (NTEC) China
NeoStem
Neuralstem
Neurologix
Nippon Zoki Pharmaceutical
Northern Therapeutics
Northwestern University
Novartis
Novo Nordisk
Novocell
NuVasive
OJSC HSCI (Human Stem Cells Institute)
OncoCyte
Opexa Therapeutics
OrbusNeich
Organ Procurement and Transplantation Network (OPTN)
Organogenesis
Orthofix
Osiris Therapeutics
Oxford BioMedica
Parcell Laboratories
Pervasis Therapeutics
Pfizer
Pharmacells
Pharmaceutical and Medical Devices Agency (PMDA) Japan
Philippines Bureau of Food and Drugs
Pluristem Therapeutics
ProChon Biotech
PsiOxus Therapeutics
Queen's University Belfast
RegenTec
Reliance Life Sciences
ReNeuron
Review Committee of Genetic Manipulation (RCGM)
Roche
Russian Ministry of Healthcare and Social Development
Rutgers University
Safeguard Scientifics
Sanofi
Saudi Food and Drug Authority (SFDA)
Shanghai Qisheng
Shanghai Sunway Biotech
Shenzhen SiBiono GeneTech
Shire Pharmaceuticals
Shire Regenerative Medicine
Skye Orthobiologics
Southern General Hospital (Scotland)
SpineSmith Partners
St. Jude's Children Research Hospital
State Food and Drug Administration (SFDA) China
Stem Cell Research Center, Peking University
StemCells
StemGen
Stempeutics Research
SUNY Upstate Medical University (Japan)
SynBio
Takara Bio
Targeted Genetics Corporation
TCA Cellular Therapy
Tel Aviv University
Tengion
Texas Heart Institute
Third Rock Ventures
TiGenix
Tissue Genesis
Translational Research Informatics Center (Foundation for Biomedical Research and Innovation)
TVM Capital
UniQure
University College London (UCL)
University of California, Los Angeles (UCLA)
University of Copenhagen
University of Geneva
University of Glasgow
University of Leuven
University of Michigan
University of Modena Centre for Regenerative Medicine
University of Pennsylvania
University of York
US Department of Defense
US Government Accountability Office (USGAO)
ViaCyte
Vical
Vindon Scientific
Virginia Commonwealth University Massey Cancer Center
Visomed
Wake Forest Institute for Regenerative Medicine
Xcellerex
Xenetic Biosciences
Yonsei University
Zimmer 

 Notes for Editors

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100